Compare PHAR & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | WVE |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | Netherlands | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 957.7M |
| IPO Year | 2020 | 2015 |
| Metric | PHAR | WVE |
|---|---|---|
| Price | $10.97 | $4.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $38.33 | $29.81 |
| AVG Volume (30 Days) | 20.7K | ★ 3.5M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $2.51 | $85.67 |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $9.62 | $4.65 |
| 52 Week High | $21.34 | $21.73 |
| Indicator | PHAR | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 42.27 | 38.55 |
| Support Level | $11.03 | N/A |
| Resistance Level | $13.51 | $6.33 |
| Average True Range (ATR) | 0.35 | 0.23 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 4.72 | 20.36 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.